Mobile

An open-label extension to a 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer’s Disease (AD) to investigate the safety and tole...

Update Il y a 5 ans
Reference: EUCTR2009-012395-27

An open-label extension to a 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer’s Disease (AD) to investigate the safety and tolerability of repeated subcutaneous injections of CAD106

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

• To evaluate the safety and tolerability of repeated injections of 150μg CAD106 in AD patients over the 66 weeks of the Extension study. • To evaluate the antibody response of repeated injections of CAD106 as measured by the titers levels of Aβ-specific IgG in serum in AD patients over the 66 weeks of the Extension study. For a detailed description of the Study objectives, please refer to Section 2 of the enclosed protocol.

Inclusion criteria

  • Alzheimer's disease

Links